image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 61.27
0.674 %
$ 13.7 B
Market Cap
19.39
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HOLX stock under the worst case scenario is HIDDEN Compared to the current market price of 61.3 USD, Hologic, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HOLX stock under the base case scenario is HIDDEN Compared to the current market price of 61.3 USD, Hologic, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one HOLX stock under the best case scenario is HIDDEN Compared to the current market price of 61.3 USD, Hologic, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HOLX

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
4.03 B REVENUE
-0.00%
970 M OPERATING INCOME
45.15%
790 M NET INCOME
73.14%
1.29 B OPERATING CASH FLOW
22.26%
-781 M INVESTING CASH FLOW
-413.48%
-1.11 B FINANCING CASH FLOW
-129.43%
1.02 B REVENUE
3.43%
230 M OPERATING INCOME
-0.13%
201 M NET INCOME
12.54%
189 M OPERATING CASH FLOW
-48.42%
-22 M INVESTING CASH FLOW
96.31%
-537 M FINANCING CASH FLOW
-845.42%
Balance Sheet Hologic, Inc.
image
Current Assets 3.82 B
Cash & Short-Term Investments 2.33 B
Receivables 600 M
Other Current Assets 889 M
Non-Current Assets 5.33 B
Long-Term Investments 96.4 M
PP&E 538 M
Other Non-Current Assets 4.7 B
25.49 %6.56 %9.71 %5.87 %51.32 %Total Assets$9.2b
Current Liabilities 1.04 B
Accounts Payable 204 M
Short-Term Debt 64.8 M
Other Current Liabilities 769 M
Non-Current Liabilities 2.99 B
Long-Term Debt 2.59 B
Other Non-Current Liabilities 396 M
5.06 %19.09 %64.41 %9.83 %Total Liabilities$4.0b
EFFICIENCY
Earnings Waterfall Hologic, Inc.
image
Revenue 4.03 B
Cost Of Revenue 1.8 B
Gross Profit 2.23 B
Operating Expenses 1.35 B
Operating Income 970 M
Other Expenses 181 M
Net Income 790 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)2b(1b)970m(181m)790mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
55.28% GROSS MARGIN
55.28%
24.07% OPERATING MARGIN
24.07%
19.59% NET MARGIN
19.59%
15.39% ROE
15.39%
8.62% ROA
8.62%
10.82% ROIC
10.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Hologic, Inc.
image
3b3b2b2b2b2b1b1b500m500m00(500m)(500m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 790 M
Depreciation & Amortization 309 M
Capital Expenditures -140 M
Stock-Based Compensation 82.3 M
Change in Working Capital 84.1 M
Others 161 M
Free Cash Flow 1.14 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Hologic, Inc.
image
Wall Street analysts predict an average 1-year price target for HOLX of $79.4 , with forecasts ranging from a low of $33 to a high of $95 .
HOLX Lowest Price Target Wall Street Target
33 USD -46.14%
HOLX Average Price Target Wall Street Target
79.4 USD 29.64%
HOLX Highest Price Target Wall Street Target
95 USD 55.05%
Price
Max Price Target
Min Price Target
Average Price Target
1001009090808070706060505040403030May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Hologic, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.9 M USD 1
6-9 MONTHS
9.31 M USD 5
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Hologic Brings in New Leadership: A Signal to Stay Put With the Stock? HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag. zacks.com - 2 weeks ago
Wayde McMillan Elected to Hologic Board of Directors MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #governance--Wayde McMillan Elected to Hologic Board of Directors. businesswire.com - 2 weeks ago
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025 MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025. businesswire.com - 2 weeks ago
Hologic (HOLX) Outperforms Broader Market: What You Need to Know Hologic (HOLX) reachead $61.77 at the closing of the latest trading day, reflecting a +0.73% change compared to its last close. zacks.com - 2 weeks ago
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 3 weeks ago
Hologic (HOLX) Advances But Underperforms Market: Key Facts In the most recent trading session, Hologic (HOLX) closed at $61.89, indicating a +0.68% shift from the previous trading day. zacks.com - 3 weeks ago
New Product Launches to Support HOLX Stock Amid Macro Issues Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets. zacks.com - 1 month ago
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip? As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold. zacks.com - 1 month ago
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 1 month ago
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report? Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store. zacks.com - 1 month ago
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock? HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential. zacks.com - 1 month ago
8. Profile Summary

Hologic, Inc. HOLX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 13.7 B
Dividend Yield 0.00%
Description Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Contact 250 Campus Drive, Marlborough, MA, 01752 https://www.hologic.com
IPO Date March 1, 1990
Employees 7063
Officers Dr. Jennifer M. Schneiders Ph.D. Division President of Diagnostic Solutions Mr. Scott Christensen Senior Vice President of Global Supply Chain, Quality & Regulatory Ms. Karleen M. Oberton CPA Chief Financial Officer Mr. Jan Verstreken Group President of International Mr. Paul Malenchini Chief Information Officer Mr. John M. Griffin J.D. General Counsel Ms. Monica Aguirre Berthelot Vice President & Chief of Staff Mr. Essex D. Mitchell Chief Operating Officer Mr. Michael J. Watts Corporate Vice President of Investor Relations Ms. Diana De Walt SPHR Senior Vice President of Global Human Resources